Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Imipramine for UVB-Induced Microvesicle Release
NCT04520217Phase 1Recruiting
- Sponsor
- Wright State University
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of imipramine in Photosensitivity, sponsored by Wright State University. Primary endpoints: Change in microvesicle particle levels from baseline in clinically photosensitive subjects at 4 hours, Change in microvesicle particle levels from baseline post topical imipramine application at 4 hours and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
imipramine
03
Conditions
Photosensitivity
Beyond the preview
Go deeper on NCT04520217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520217.